FDA Grants Fast Track Designation for Custirsen for mCRPC

Share this content:
BPA Exposure May Raise Prostate Cancer Risk
BPA Exposure May Raise Prostate Cancer Risk

OncoGenex announced that the FDA has granted Fast Track designation to custirsen when given in combination with cabazitaxel/prednisone for the treatment of metastatic castration-resistant prostate cancer (CRPC) after prior treatment with a docetaxel-containing regimen.

Custirsen (OGX-011) is designed to block the production of the protein clusterin, which then alters tumor dynamics, slows tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.

RELATED: Male Reproductive Cancers Resource Center

OncoGenex is planning on enrolling approximately 630 men into its international, randomized, open-label Phase 3 AFFINITY trial. The study is designed to evaluate the survival outcomes of prostate cancer patients treated with custirsen and second-line chemotherapy cabazitaxel/prednisone compared to second-line chemotherapy alone.

The FDA has previously granted custirsen Fast Track status for the treatment of metastatic non-small cell lung cancer (NSCLC) and for mCRPC.

For more information call (425) 686-1500 or visit OncoGenex.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs